Aktienanalyse zu Chronoscale Corp (CHRN)CHRNChronoscale Corp

ChronoScale Corporation, formerly Ekso Bionics Holdings, Inc., designs, develops, and markets exoskeleton products. Its exoskeleton technology serves people with physical disabilities or impairments in both physical rehabilitation and mobility. The Company operates as one segment with two markets: Enterprise Health and Personal Health. Its products include EksoNR, which is a wearable robotic exoskeleton designed for a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower limb-powered exoskeleton; Ekso Indego Personal is a lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. It enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate, stand and walk again. It assists people to perform challenging repetitive tasks for extended periods. It operates in the Healthcare sector.

Ekso Bionics Holdings, Inc. is not a good buy right now due to its poor technical indicators and financial performance. The current price is $18.74, and the RSI is at a low 21.568, indicating oversold conditions. Additionally, the company has a significant forward P/E ratio of 0, reflecting no earnings expectations, and a gross margin of only 50.16%, which is declining. The main risk is the recent 5-day price change of -21.41%, suggesting strong downward momentum.